Bruno Ferraz-de-Souza, MD, PhD

November 09, 2023

Bruno Ferraz-de-Souza, MD, PhD, is an Associate Professor and Chair of the Basic & Clinical Sciences Domain at the University of Notre Dame Australia School of Medicine in Fremantle, Western Australia, and also Honorary Principal Investigator and Postgraduate Supervisor in Endocrinology at the University of Sao Paulo School of Medicine, in Sao Paulo, Brazil. Dr. Ferraz-de-Souza graduated in medicine from the University of Sao Paulo, where he also undertook clinical training as an endocrinologist under the supervision of Berenice Mendonca. Upon obtaining board certification in Brazil, he embarked on a PhD at University College London, UK, in John Achermann's lab, investigating human adrenal development. More recently, his research has focused on the molecular bases of rare and common endocrinopathies, with a focus on bone metabolism. 

Dr. Ferraz-de-Souza is interested in scientific communication and medical education, and passionate about diversity, equity and inclusion. He has served as an Associate Editor for the Journal of the Endocrine Society (JES) and Endocrine Connections, and as Deputy Editor-in-Chief for the Archives of Endocrinology and Metabolism. He has been active as a member leader of the Brazilian Society for Endocrinology and Metabolism (SBEM), more recently as President of the Basic Endocrinology department and as the inaugural President of the Committee on Diversity, Equity and Inclusion. Dr. Ferraz-de-Souza has long identified the Endocrine Society as his scientific and professional home, and has served as Chair of the Committee on Diversity and Inclusion (CODI) and of the Publications Core Committee (PCC). During his tenure in CODI, his proudest accomplishments were the creation of the LGBTQ+ and Allies Reception during ENDO and the Diversity Town Hall for the Society's leadership.

 
Last Updated:
Back to top

Who We Are

For 100 years, the Endocrine Society has been at the forefront of hormone science and public health. Read about our history and how we continue to serve the endocrine community.